Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.The names of the study intervention groups involved in this study are:Palliative care (PEACE) plus usual oncology careUsual care (standard oncology care)Participation in this research study is expected to last for up to 2 years.It is expected that about 90 people will take part in this research study.

Inclusion Criteria:Age 18 years or older.Ability to complete surveys in English or with assistance of an interpreter.Diagnosis of a hematologic malignancy.Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.Exclusion Criteria:Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.Already receiving palliative care (PC).